The newly licensed intrathecal gene therapy expands life-changing treatment options for children and adults affected by SMA DUBAI, United Arab Emirates–(BUSINESSThe newly licensed intrathecal gene therapy expands life-changing treatment options for children and adults affected by SMA DUBAI, United Arab Emirates–(BUSINESS

UAE’s Medcare Treats First International SMA Patient With Revolutionary Intrathecal Gene Therapy

2025/12/30 22:32

The newly licensed intrathecal gene therapy expands life-changing treatment options for children and adults affected by SMA

DUBAI, United Arab Emirates–(BUSINESS WIRE)–Medcare Women & Children Hospital has successfully administered a pioneering intrathecal gene therapy for Spinal Muscular Atrophy (SMA) to Hulus, a three-year-old patient from Turkey. This milestone positions Medcare among the first private healthcare providers worldwide to offer this innovative treatment to an older international patient, overcoming previous age and weight limitations.

SMA is a rare neuromuscular disorder that progressively weakens muscles responsible for movement and breathing. This newly licensed one-time therapy addresses the root genetic cause by delivering a functional SMN1 gene.

For Hulus, whose daily routine earlier depended on intensive physiotherapy and hydrotherapy, the procedure from Medcare offered a promising alternative to lifelong injections. His father, Mustafa, shared that despite years of rehabilitation, the therapy has renewed hope for greater independence and quality of life for his son.

“This is a defining moment for SMA care in the region,” said Dr. Shanila Laiju, Group CEO of Medcare Hospitals & Medical Centres. “Families whose children were previously ineligible for gene therapy now have access to a revolutionary treatment that can significantly improve outcomes. This reflects Medcare’s long-standing commitment to children with rare diseases, supported by specialised expertise and advanced infrastructure.”

Since 2020, Medcare has treated more than 180 children with SMA, welcoming families from Iran, Turkey, Nepal, Romania, Russia, Kazakhstan, Kyrgyzstan, Ukraine, Belarus, Lebanon, India, and Ethiopia, reinforcing Dubai’s role as a strategic global hub for medical tourism and paediatric genetic care.

“Older and heavier patients can now benefit from transformative therapy,” said Dr. Vivek Mundada, Consultant Paediatric Neurologist. “This shifts SMA care beyond infant survival toward preserving mobility, independence, and respiratory function in older patients.”

Medcare delivers SMA care through a multidisciplinary model encompassing neurology, pulmonology, orthopaedics, rehabilitation, genetic counselling, and long-term follow-up for international patients.

Aligned with the UAE’s medical tourism vision, Medcare, part of Aster DM Healthcare, continues to invest in advanced technologies, specialised units, and clinical talent to provide timely, high-quality care for rare and complex conditions, including Spinal Muscular Atrophy.

Source: AETOSWire

Contacts

Rania Roxana

Medcare Hospital

rania.akkela@medcarehospital.com

시장 기회
Cyberlife 로고
Cyberlife 가격(LIFE)
$0.0284
$0.0284$0.0284
-1.04%
USD
Cyberlife (LIFE) 실시간 가격 차트
면책 조항: 본 사이트에 재게시된 글들은 공개 플랫폼에서 가져온 것으로 정보 제공 목적으로만 제공됩니다. 이는 반드시 MEXC의 견해를 반영하는 것은 아닙니다. 모든 권리는 원저자에게 있습니다. 제3자의 권리를 침해하는 콘텐츠가 있다고 판단될 경우, service@support.mexc.com으로 연락하여 삭제 요청을 해주시기 바랍니다. MEXC는 콘텐츠의 정확성, 완전성 또는 시의적절성에 대해 어떠한 보증도 하지 않으며, 제공된 정보에 기반하여 취해진 어떠한 조치에 대해서도 책임을 지지 않습니다. 본 콘텐츠는 금융, 법률 또는 기타 전문적인 조언을 구성하지 않으며, MEXC의 추천이나 보증으로 간주되어서는 안 됩니다.